Loss of function alleles in the UGT1A1 gene are associated with drug-related hyperbilirubinemia; carriers of this variant treated with the PI atazanavir develop more severe hyperbilirubinemia, since atazanavir acts as an inhibitor to UGT1A1 [25]. This evidence concerns the gene UGT1A1 and Hyperbilirubinemia.